PD-Rx Pharmaceuticals, Inc. (PDRX) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PD-Rx Pharmaceuticals, Inc. (PDRX) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026PD-Rx Pharmaceuticals, Inc. (PDRX) Resumen de Asistencia Médica y Tuberías
PD-Rx Pharmaceuticals, Inc., established in 1986, operates within the medical distribution sector, providing prepackaged medications and dispensing solutions to healthcare providers across the United States. The company's offerings include a variety of medications, web-based prescription tracking, and pharmaceutical sampling programs, serving physicians, pharmacies, and medical clinics.
Tesis de Inversión
PD-Rx Pharmaceuticals, Inc. operates in the niche market of prepackaged pharmaceutical distribution, offering convenience to healthcare providers. However, the company's negative profit margin of -1.4% and a P/E ratio of -19.98 indicate financial challenges. The beta of -1366978.48 suggests an inverse correlation with the market, which can be both a risk and an opportunity. Growth catalysts include expanding its PD-Rx Net platform and pharmaceutical sampling programs. The company's ability to achieve profitability and manage its cost structure will be critical for long-term success. Investors should closely monitor its financial performance and competitive positioning within the medical distribution sector.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.01 billion indicates a small-cap company.
- Negative P/E ratio of -19.98 suggests the company is currently not profitable.
- Profit margin of -1.4% reflects operational inefficiencies or pricing pressures.
- Beta of -1366978.48 indicates an inverse correlation with the market, suggesting the stock may move opposite to market trends.
- No dividend yield, indicating the company is not currently returning profits to shareholders.
Competidores y Pares
Fortalezas
- Established presence in the prepackaged pharmaceutical distribution market.
- Proprietary PD-Rx Net platform for prescription tracking.
- Comprehensive range of prepackaged medications.
- Pharmaceutical sampling program design expertise.
Debilidades
- Negative profit margin indicates financial instability.
- Small market capitalization limits access to capital.
- High beta suggests significant volatility.
- Dependence on a niche market segment.
Catalizadores
- Ongoing: Expansion of PD-Rx Net platform to attract more customers and increase subscription revenue.
- Ongoing: Strategic partnerships with medical clinics to drive sales and expand market reach.
- Upcoming: Potential regulatory changes in the pharmaceutical industry that could benefit smaller distributors.
- Ongoing: Development of new pharmaceutical sampling programs to reduce costs for MCOs.
- Ongoing: Geographic expansion to new regions within the United States to tap into untapped markets.
Riesgos
- Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.
- Potential: Economic downturn affecting healthcare spending and reducing demand for pharmaceutical products.
- Potential: Regulatory changes impacting the pharmaceutical industry and increasing compliance costs.
- Potential: Product liability claims arising from the distribution of pharmaceutical products.
- Ongoing: The company's financial instability, with a negative profit margin and P/E ratio.
Oportunidades de crecimiento
- Expansion of PD-Rx Net Platform: The company can focus on enhancing and expanding its PD-Rx Net platform, a web-based application that tracks prescriptions filled at the point of care. By adding more features and integrations, PD-Rx can attract more physicians and pharmacies, increasing its market share. The market for healthcare IT solutions is projected to reach $390 billion by 2027, offering a significant growth opportunity.
- Pharmaceutical Sampling Program Design: PD-Rx Pharmaceuticals can further develop its pharmaceutical sampling program design to reduce pharmaceutical costs for MCOs. This program allows medical professionals to offer pre-filled prescriptions to patients free of charge. As healthcare costs continue to rise, MCOs are actively seeking cost-saving solutions, making this a viable growth area. The pharmaceutical sampling market is estimated to be worth $20 billion annually.
- Strategic Partnerships with Medical Clinics: Forming strategic partnerships with medical clinics to provide prepackaged medications and dispensing solutions can drive revenue growth. By offering a comprehensive suite of services, PD-Rx can become an integral part of the clinic's operations, ensuring a steady stream of orders. The number of medical clinics is growing at a rate of 3% annually, presenting a large potential market.
- Geographic Expansion: Expanding its operations to new geographic regions within the United States can significantly increase PD-Rx's customer base. By targeting states with a high concentration of physicians and pharmacies, the company can capitalize on untapped markets. The US pharmaceutical market is the largest in the world, with a value of over $500 billion, offering ample opportunities for growth.
- Development of Specialty Medication Packaging: Focusing on the development of specialized packaging solutions for specialty medications can cater to a growing niche market. Specialty medications often require specific handling and storage conditions, creating a demand for specialized packaging. The specialty pharmaceutical market is growing at a rate of 8% annually, driven by the increasing prevalence of chronic diseases and the development of innovative therapies.
Oportunidades
- Expansion of PD-Rx Net platform to attract more customers.
- Strategic partnerships with medical clinics to increase sales.
- Geographic expansion to new regions within the United States.
- Development of specialty medication packaging solutions.
Amenazas
- Increasing competition from larger pharmaceutical distributors.
- Regulatory changes impacting the pharmaceutical industry.
- Economic downturn affecting healthcare spending.
- Potential for product liability claims.
Ventajas competitivas
- Established relationships with physicians, pharmacies, and medical clinics.
- Proprietary PD-Rx Net web-based application for prescription tracking.
- Specialized expertise in repackaging and distributing prepackaged medications.
- Pharmaceutical sampling program design capabilities.
Acerca de PDRX
PD-Rx Pharmaceuticals, Inc., founded in 1986 and headquartered in Oklahoma City, Oklahoma, operates within the healthcare industry, specializing in the repackaging and distribution of prepackaged pharmaceutical products. The company serves a diverse clientele, including physicians, pharmacies, and medical clinics throughout the United States. PD-Rx Pharmaceuticals offers a comprehensive portfolio of approximately 2,600 prepackaged medications, encompassing creams, ointments, ophthalmics, otics, liquids, and suspensions. Beyond its distribution capabilities, PD-Rx Pharmaceuticals provides technological solutions to streamline prescription management. PD-Rx Net, a web-based application, enables healthcare providers to track prescriptions filled at the point of care and print prescription labels for onsite dispensing. Additionally, the company offers a manual dispensing system, complete with recordkeeping labels, designed for physician dispensing customers. PD-Rx Pharmaceuticals also distinguishes itself through its commitment to customer support and cost-effectiveness. The company provides professional assistance from staffed pharmacists and physicians, ensuring that clients receive expert guidance and support. Furthermore, PD-Rx Pharmaceuticals designs pharmaceutical sampling programs aimed at reducing pharmaceutical costs for Managed Care Organizations (MCOs), while also enabling medical professionals to offer pre-filled prescriptions to patients free of charge.
Qué hacen
- Repackages and distributes prepackaged pharmaceutical products.
- Provides approximately 2,600 prepackaged medications.
- Offers creams, ointments, ophthalmics, otics, liquids, and suspensions.
- Provides PD-Rx Net, a web-based application for prescription tracking.
- Offers a manual dispensing system with recordkeeping labels.
- Provides professional assistance from staffed pharmacists and physicians.
- Designs pharmaceutical sampling programs to reduce MCO's pharmaceutical costs.
Modelo de Negocio
- Generates revenue through the sale of prepackaged medications to physicians, pharmacies, and medical clinics.
- Offers PD-Rx Net subscription for prescription tracking and label printing.
- Provides pharmaceutical sampling program design services to MCOs.
- Offers manual dispensing systems and related supplies.
Contexto de la Industria
PD-Rx Pharmaceuticals, Inc. operates within the medical distribution industry, which is characterized by increasing demand for efficient pharmaceutical supply chains and point-of-care dispensing solutions. The industry is influenced by factors such as regulatory changes, technological advancements, and the growing emphasis on cost containment within the healthcare system. Competitors like CPIVF, FZMD, IDXG, KOSK, and MVMDF operate in similar spaces, providing various pharmaceutical products and services. PD-Rx Pharmaceuticals differentiates itself through its focus on prepackaged medications and its PD-Rx Net platform.
Clientes Clave
- Physicians
- Pharmacies
- Medical Clinics
Finanzas
Gráfico e información
Precio de la acción de PD-Rx Pharmaceuticals, Inc. (PDRX): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para PDRX.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para PDRX.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para PDRX.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de PDRX en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Robert D. Holsey
CEO
Robert D. Holsey serves as the Chief Executive Officer of PD-Rx Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical distribution industry. He has been involved in various aspects of the business, including sales, marketing, and operations. Holsey's leadership is focused on driving growth and profitability through strategic partnerships and innovative solutions. His expertise in the healthcare sector allows him to navigate the complexities of the market and identify opportunities for expansion.
Historial: Under Robert D. Holsey's leadership, PD-Rx Pharmaceuticals, Inc. has focused on expanding its product offerings and strengthening its customer relationships. Key milestones include the development and launch of the PD-Rx Net platform and the implementation of pharmaceutical sampling programs. Despite financial challenges, Holsey has worked to streamline operations and improve efficiency. The company's focus remains on providing value-added services to its clients.
Información del mercado OTC de PDRX
The OTC Other tier represents the lowest tier of the OTC market, indicating that PD-Rx Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases the risk of investing in PDRX.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- Lack of regulatory oversight on the OTC Other tier increases the risk of fraud or mismanagement.
- The company's financial performance is currently weak, with a negative profit margin and P/E ratio.
- Small market capitalization makes the company vulnerable to market fluctuations.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's competitive positioning within the medical distribution industry.
- Analyze the company's revenue streams and customer base.
- Determine the company's debt levels and cash flow.
- Understand the company's regulatory compliance and legal risks.
- Assess the liquidity of the stock and the potential for price volatility.
- The company has been in operation since 1986, indicating a long history in the industry.
- PD-Rx Pharmaceuticals, Inc. provides a specific service within the healthcare industry.
- The company has a CEO, Robert D. Holsey, suggesting leadership and direction.
- The company offers a web-based application, PD-Rx Net, suggesting technological capabilities.
- The company serves physicians, pharmacies, and medical clinics, indicating a customer base.
PDRX Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar PDRX?
PD-Rx Pharmaceuticals, Inc. (PDRX) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Established presence in the prepackaged pharmaceutical distribution market.. Riesgo principal a monitorear: Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de PDRX?
PDRX actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de PDRX?
Los precios de PDRX se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre PDRX?
La cobertura de analistas para PDRX incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en PDRX?
Las categorías de riesgo para PDRX incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de PDRX?
La relación P/E para PDRX compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está PDRX sobrevalorada o infravalorada?
Determinar si PD-Rx Pharmaceuticals, Inc. (PDRX) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de PDRX?
PD-Rx Pharmaceuticals, Inc. (PDRX) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide further insights.